Laureate Pharma has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, a biotechnology company that develops targeted therapies and safer solutions for immune modulation and related medical needs. Under the agreement, Laureate will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Terms of the agreement were not disclosed.
   
"We are pleased to work closely with Tolera to accelerate their antibody therapeutics program to clinic," said Robert J. Broeze, Ph. D., president and chief executive officer of Laureate. "We are committed to providing Tolera with superior services to help them achieve their manufacturing objectives."
   
"We are excited to work with Laureate, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities in both clinical and commercial-grade materials can support our aggressive development and commercial plans," said John J. Puisis, president and chief executive officer of Tolera. "We look forward to our partnership with Laureate in utilizing their specialized experience in the manufacture of monoclonal antibodies."

News from our sister sites